TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02765126

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Intramuscular standard seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Intramuscular standard seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Description: Intramuscular standard seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular DTaP vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular DTaP vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: Intramuscular DTaP vaccine
Study: NCT03673605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Description: Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Ramipril
Study: NCT03673605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT03659149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation I
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation I
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 formulation II
Description: 1 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330+D086
Description: 2 tablet administered before the breakfast(single-dose)
Study: NCT02186054

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI examinations
Description: Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
Study: NCT02614807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
Study: NCT01833260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Study: NCT01007123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A3309
Description: A3309 in three different dosage levels or placebo once daily for the duration of the study
Study: NCT00076336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600mg/day oral tablet for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100mg/day oral tablet for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.
Study: NCT01206283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Lund concept
Description: After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral perfusion pressure-targeted therapy
Description: * ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);
Study: NCT00524589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral
Study: NCT02947529

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous dose
Study: NCT03929198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: 6 week Diet, Exercise training, Behavioral modification
Study: NCT04085952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dermal graft (ARCUS repliform) for anterior colporrhaphy
Description: At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture based anterior colporrhaphy
Description: At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
Study: NCT04027452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traumatic memory reactivation
Description: 125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral memory reactivation
Description: 125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.
Study: NCT03719352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Deep dry needling
Description: Deep dry needling until achieving twitch response of the muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Superficial dry needling
Description: Superficial dry needling to achieve sensitive pain with needle rotation
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain apple compote control
Study: NCT03356795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervical cancer-specific CAR-T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study: NCT04096469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
Study: NCT01676649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2
Study: NCT00524589

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study: NCT02060994

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00881764

Intervention type: PROCEDURE
Intervention: Inguinal hernia surgery
Description: Non-experimental procedure

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Non-experimental procedure/treatment
Study: NCT04101162

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: shear waves elastography; liver biopsy
Description: Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: shear waves elastography; liver biopsy
Description: Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
Study: NCT04214470

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT00887094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Description: Aerobic exercise (on a cycle ergometer, for 50 min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute aerobic-resistance exercise
Description: Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
Study: NCT04123340

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Additional intraprocedural pre-ablation CT-scan
Description: In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
Study: NCT02243306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Round, biconvex, white film coated tablet containing 5 mg GSK1278863.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
Study: NCT01888965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed
Study: NCT04143256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS 5% Virginia Tobacco
Description: JUUL ENDS Virginia Tobacco 5% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Virginia Tobacco ENDS
Description: JUUL ENDS Virginia Tobacco 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Mint ENDS
Description: JUUL ENDS Mint 5% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Mint ENDS
Description: JUUL ENDS Mint 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Menthol ENDS
Description: JUUL ENDS Menthol 5% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Menthol ENDS
Description: JUUL ENDS Menthol 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% Mango ENDS
Description: JUUL ENDS Mango 5% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 3% Mango ENDS
Description: JUUL ENDS Mango 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Cigarette, Non-menthol - Marlboro Gold King Size
Description: US Cigarette, Non-menthol - Marlboro Gold King Size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Cigarette, Menthol - Newport King Size
Description: US Cigarette, Menthol - Newport King Size
Study: NCT02668679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation of children during gastroscopy with and without the presence of dream doctor
Description: children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sedation of children during gastroscopy with and without the presence of dream doctor
Description: children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of stress with PPI and GSR
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: evaluation of stress with PPI and GSR
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood specimens for stress hormones
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood specimens for stress hormones
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological indices for evaluation of stress
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological indices for evaluation of stress
Description: evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
Study: NCT03523403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apples
Description: 3 whole Ontario-grown Gala apples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apples
Description: 3 whole Ontario-grown Gala apples
Study: NCT03996655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Reversal of neuromuscular blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of neuromuscular blockers
Study: NCT00914095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: 10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets of placebo 3 times a day
Study: NCT04340089

Intervention type: BEHAVIORAL
Intervention: squatting on the toilet
Description: the patients could go to squatting on the toilet at any time as they want to after taking the capsule
Study: NCT01666392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
Study: NCT00083616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
Study: NCT00738322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Solution for iv infusion, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl solution for iv infusion, single dose